Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | YL-13027 |
Trade Name | |
Synonyms | YL 13027|YL13027 |
Drug Descriptions |
YL-13027 inhibits type 1 TGF-beta receptor, which may modulate tumor microenvironment, potentially leading to inhibition of tumor growth (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3098-3098). |
DrugClasses | TGFBR1 inhibitor 16 |
CAS Registry Number | NA |
NCIT ID | C172107 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Gemcitabine + Nab-paclitaxel + YL-13027 | Gemcitabine Nab-paclitaxel YL-13027 | 0 | 1 |
YL-13027 | YL-13027 | 0 | 1 |